Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2025-05-02 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings Classification · 1% confidence The document is titled "Company Announcement" and discusses Genmab's intention to submit a supplemental Biologics License Application (sBLA) to the FDA based on positive Phase 3 trial results for epcoritamab. It provides clinical trial updates, scientific background, and contact information, characteristic of a press release or regulatory disclosure regarding clinical development milestones. Since it is an announcement about a regulatory submission and clinical data, and not the full financial report (10-K), an earnings release (ER), or a formal proxy/shareholder document, it best fits the category of a general regulatory announcement or a specific announcement related to drug development/regulatory action. Given the options, this is a significant corporate announcement that doesn't fit the specific financial report types. It is most closely aligned with a general regulatory filing or announcement, which points towards RNS (Regulatory Filings) as the most appropriate general category, although it functions like an Earnings Release (ER) in terms of timing/purpose, but focuses on regulatory submission intent rather than financial results. However, since it is a formal announcement of a regulatory action plan (sBLA submission), and not a financial result release, RNS is the best fit as a broad regulatory/corporate disclosure, or potentially LTR if it were about legal proceedings, which it is not. Given the context of FDA submission plans, RNS (Regulatory Filings) is the most suitable fallback for a major corporate/regulatory update that isn't a standard financial report.
2025-05-02 English
Regulatory Filings 2025
Regulatory Filings Classification · 1% confidence The document is titled 'Company Announcement' and details Genmab's intention to submit a supplemental Biologics License Application (sBLA) to the FDA based on positive Phase 3 trial results. It discusses clinical trial data, regulatory submissions (sBLA), and future plans for presenting results at a medical conference. This content is a specific update regarding product development and regulatory progress, not a comprehensive annual report (10-K), a general earnings release (ER), or a formal transcript (CT). Since it is a specific announcement about a regulatory/development milestone that doesn't fit neatly into the core financial reports (10-K, IR, MRQ), it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the submission implied a major commercial event, but RNS is the most appropriate fallback for specific, non-standard regulatory/clinical news releases that aren't explicitly covered elsewhere. Upon reviewing the definitions, this is a specific announcement about a regulatory action (sBLA submission) and clinical data. It is not a general 'Report Publication Announcement' (RPA) because it is announcing the *action* (submission) rather than announcing the *publication* of a previously prepared report (like an Annual Report or Interim Report). Given the nature of announcing clinical trial progress and regulatory filings, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most suitable category.
2025-05-02 English
6-K
Foreign Filer Report
2025-04-28 English
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 1% confidence The document is titled "Transactions in Connection with Share Buy-back Program" and details the number of shares repurchased by Genmab A/S between April 21 and April 25, 2025, as part of an ongoing program announced on March 25, 2025. This activity specifically relates to the company buying back its own shares to reduce capital and fulfill obligations. This directly matches the definition for 'Transaction in Own Shares' (Code: POS). It is not a general regulatory filing (RNS) because it describes a specific, defined corporate action.
2025-04-28 English
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document consists entirely of tables detailing individual stock transactions (Issuer, Date, Time, Quantity, Price, Venue) for GENMAB A/S on a specific date (22-Apr-2025). This format strongly indicates a report of transactions in the company's own shares, often related to buybacks or insider dealings, but the context of simple trade logs points most directly to share repurchase/issuance activity or insider trading reports. Since the data is a log of transactions rather than a formal declaration of a director's personal trade (DIRS) or a general capital change announcement (SHA), and given the presence of 'Quantity' and 'Price' data typical of market activity reporting, the most fitting category is 'Transaction in Own Shares' (POS), which covers share repurchase/issuance reports. If this were a regulatory filing detailing insider trades, DIRS would be considered, but the raw trade log format aligns better with POS or potentially a general regulatory filing (RNS) if it were a mandatory disclosure of market activity. Given the options, POS is the best fit for a detailed log of share movements.
2025-04-28 English
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 1% confidence The document is titled "Transactions in Connection with Share Buy-back Program" and details the number of shares repurchased by Genmab A/S between April 21 and April 25, 2025, under an existing buy-back program announced on March 25, 2025. This content specifically reports on the company's own share transactions (repurchases). According to the definitions, the category 'Transaction in Own Shares (Code: POS)' covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document is a detailed report of these transactions, not just an announcement of a future report.
2025-04-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.